Beam Therapeutics Inc. (BEAM) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$32.33
Price Target
$40.83
Target Range
$26.00 — $74.00
Analyst Rating
Buy
Forward P/E—
Trailing P/E-39.9x
Forward PEG—
Implied Growth-474.7%
Median Target$38.00
Analyst Spread117.6%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$26
-19.6%
Consensus
$41
+26.3%
Bull Case
$74
+128.9%
BEAM Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Beam Therapeutics Inc. (BEAM) has a Wall Street consensus price target of $40.83, based on estimates from 27 covering analysts. With the stock currently trading at $32.33, this represents a potential upside of +26.3%. The company has a market capitalization of $3.32B.
Analyst price targets range from a low of $26.00 to a high of $74.00, representing a 118% spread in expectations. The median target of $38.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BEAM trades at a trailing P/E of -39.9x. Analysts expect EPS to grow -474.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+464.7%
Avg Forward P/E32.9x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 EDITEditas Medicine, Inc. | $311M | $3.17 | $6.00 | +89.0% | Buy | — | 25 |
 CRSPCRISPR Therapeutics AG | $5.3B | $55.08 | $63.00 | +14.4% | Buy | — | 38 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.85 | $20.88 | +50.8% | Buy | — | 39 |
 PRMEPrime Medicine, Inc. | $616M | $3.41 | $17.25 | +405.9% | Buy | — | 9 |
 SGMOSangamo Therapeutics, Inc. | $38M | $0.18 | $7.25 | +3982.2% | Hold | — | 14 |
 RCKTRocket Pharmaceuticals, Inc. | $418M | $3.86 | $5.00 | +29.5% | Buy | — | 19 |
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.93 | $51.50 | +98.6% | Buy | — | 33 |
 KRYSKrystal Biotech, Inc. | $8.5B | $288.89 | $332.75 | +15.2% | Buy | 38.3x | 17 |
 ILMNIllumina, Inc. | $21.7B | $142.58 | $147.38 | +3.4% | Buy | 27.5x | 50 |
 PACBPacific Biosciences of California, Inc. | $516M | $1.71 | $1.00 | -41.5% | Buy | — | 18 |
Upside Potential Comparison
SGMOPRMERAREEDITNTLARCKTKRYSCRSPSee BEAM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BEAM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BEAM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBEAM — Frequently Asked Questions
Quick answers to the most common questions about buying BEAM stock.
What is the BEAM stock price target for 2026?
The consensus Wall Street price target for BEAM is $40.83, representing 26.3% upside from the current price of $32.333. With 27 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is BEAM a buy, sell, or hold?
BEAM has a consensus rating of "Buy" based on 27 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $40.83 implies 26.3% upside from current levels.
Is BEAM stock overvalued or undervalued?
BEAM's current price is $32.333 with a consensus target of $40.83 (26.3% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can BEAM stock go?
The most bullish Wall Street analyst has a price target of $74 for BEAM, while the most conservative target is $26. The consensus of $40.83 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover BEAM stock?
BEAM is heavily covered by Wall Street, with 27 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 18 have Buy ratings, 8 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the BEAM stock forecast?
The 12-month BEAM stock forecast based on 27 Wall Street analysts shows a consensus price target of $40.83, with estimates ranging from $26 (bear case) to $74 (bull case). The median consensus rating is "Buy".
Should I buy BEAM stock?
Wall Street analysts are very optimistic on BEAM, with a "Buy" consensus rating and $40.83 price target (26.3% upside). 18 of 27 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do BEAM price targets vary so much?
BEAM analyst price targets range from $26 to $74, a 118% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40.83 consensus represents the middle ground.